- Kymera Therapeutics press release ( NASDAQ: KYMR ): Q2 GAAP EPS of -$0.78 misses by $0.08 .
- Revenue of $11.51M (-37.9% Y/Y) misses by $3.46M .
- “Kymera has made strong progress, dosing patients in our three first-in-class clinical programs and advancing our mission to build a fully integrated medicines company,” said Nello Mainolfi, PhD, Co-Founder, President and CEO. “We are on track to deliver clinical data before year end for all three programs, including our KT-474 Phase 1 patient cohort, where we expect to demonstrate the ability of KT-474 to degrade IRAK4 and impact disease relevant biomarkers in the skin and blood of HS and AD patients. We also plan to share initial safety and proof-of-mechanism data for our two oncology programs, KT-413 and KT-333. With a cash runway into 2025, we are well-financed and poised to deliver clinical results in the second half of this year that reinforce the exciting and broad potential of our targeted protein degradation pipeline and platform.”
For further details see:
Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M